Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board (Q33703096)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board (English)

1 reference

Europe PubMed Central

28 July 2017

multiple myeloma

1 reference

based on heuristic

inferred from title

peripheral neuropathy

1 reference

based on heuristic

inferred from title

author name string

Joseph D Tariman

1

1 reference

Europe PubMed Central

28 July 2017

Ginger Love

2

1 reference

Europe PubMed Central

28 July 2017

Emily McCullagh

3

1 reference

Europe PubMed Central

28 July 2017

Stacey Sandifer

4

1 reference

Europe PubMed Central

28 July 2017

IMF Nurse Leadership Board

5

1 reference

Europe PubMed Central

28 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 June 2008

1 reference

Europe PubMed Central

28 July 2017

Clinical Journal of Oncology Nursing

1 reference

Europe PubMed Central

28 July 2017

12

1 reference

Europe PubMed Central

28 July 2017

3 Suppl

1 reference

Europe PubMed Central

28 July 2017

29-36

1 reference

Europe PubMed Central

28 July 2017

Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Novel therapeutic avenues in myeloma: changing the treatment paradigm.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

The emerging role of novel therapies for the treatment of relapsed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Advances in oral therapy in the treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Neurological aspects of multiple myeloma and related disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Updating your peripheral neuropathy "know-how".

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Thalidomide: current therapeutic uses and management of its toxicities.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Understanding peripheral neuropathy in patients with cancer: background and patient assessment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Thalidomide in cancer: potential uses and limitations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Neuropathy in multiple myeloma treated with thalidomide: a prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

30 October 2018

Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

30 October 2018

Bradycardia during therapy for multiple myeloma with thalidomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

30 October 2018

Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

30 October 2018

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

1 reference

https://pubmed.ncbi.nlm.nih.gov/18490255

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Total neuropathy score: validation and reliability study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18490255

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuropathies associated with paraproteinemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18490255

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy-induced peripheral neuropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18490255

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring

1 reference

https://pubmed.ncbi.nlm.nih.gov/18490255

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1188/08.CJON.S1.29-35

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33703096&oldid=1634384959"